Meeting the needs of a new era

Svar is rooted in scientific excellence and anchored by strong collaboration with leading experts. Its headquarters are in Malmö, including diagnostics, bioanalytical, and R&D laboratory space, as well as a production site. The company also has a specialized cell engineering center in Paris. Svar’s journey, from its origins as Euro Diagnostica to today’s broad product & laboratory service portfolio, reflects a commitment to meeting the changing needs of pharma, biotech, and diagnostic customers.

Today, Svar Life Science plays a central role in supporting advanced therapies, including AAV-based approaches, multispecific antibodies, and targeted immune therapeutics, all while maintaining a strong focus on complement research.

As CEO Anne Thjømøe explains,

“We’ve built on the solid foundation of immunoassays development, but our solutions now go far beyond. We’re meeting the needs of a new era in pharmaceutical development, one defined by innovation, regulation, and precision.”

Uniquely adapted assay solutions

This year, Svar is celebrating 20 years of the Complement Wieslab® (formerly Wielisa) kits, developed with leading experts and recognized as the gold standard for complement system analysis. These kits are essential for both clinical assessment and the development of next-generation complement-targeting drugs. Svar’s commitment to advancing the field extends beyond technology and services. Each year, the company sponsors the Svar Complement Excellence Award in collaboration with the complement research community. The award recognizes and supports outstanding researchers and physicians who make a significant contribution to complement research.

Svar’s portfolio also includes GxPcompliant CRO and ISO 15189-accredited clinical laboratory services, and custom cell-based assay development, which ensures readiness for evolving science and regulatory demands. “Today, we offer pharma and biotech uniquely adapted assay solutions that help bring sophisticated therapies to market faster, smarter, and with confidence,” adds Thjømøe.

Anne Thjømøe outlines Svar’s vision going forward. “For the coming 20 years our journey is about accelerating immune innovation, building meaningful partnerships, and helping shape a healthier future for patients worldwide.”